Folosim cookie-uri pentru a îmbunătăți experiența pe site. Pentru detalii, citește Politica de confidențialitate.

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

23.02.2026 16:26 | The Guardian World

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectationsBusiness live – latest updatesThe owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials.Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations. Continue reading...

🔗 Citește articolul complet pe The Guardian World